Metrics as of 10/16/2026, 08:37 AM (Berlin time), refresh in progress.
Fractyl Health Stock
Fractyl Health, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Harith Rajagopalan
- Employees
- 100
- Market cap
- $21 M
- IPO
- 02/02/2024
- Web
- fractyl.com
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar…
Fractyl Health stock: price history
1D
-62.7%
1W
-64.9%
1M
-77.0%
6M
-77.3%
YTD
-94.1%
1Y
-89.8%
2Y
-94.8%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~29% weaker price swings than usual
Fractyl Health stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Fractyl Health
Analyst assessment of Fractyl Health
PRICE TARGET LOW
US$2.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 04/06/2026
Fractyl Health stock metrics
P/E
-0.12
P/B
-12.31
EV/EBITDA
-0.33
RETURN ON EQUITY
1,533.8%
NET MARGIN
0.0%
DEBT/EQUITY
-36.48
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.5%
FLOAT SHARES
11,334,971
AVG. DAILY VOLUME (30D)
652,002
Insider transactions (SEC)
BRADLEY WILLIAM
Royan Ajay
Rajagopalan Harith
Sheffield Ian
BRADLEY WILLIAM
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Fractyl Health stock
What does Fractyl Health do?
Fractyl Health, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Harith Rajagopalan, the company employs around 100 people.
The IPO was on 02/02/2024; the stock trades on NASDAQ under the ticker GUTS.
What do analysts say about Fractyl Health stock?
3 analysts rate the stock, the consensus is Buy (as of 04/06/2026).
The average price target is US$5.00, ranging from US$2.00 to US$8.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Fractyl Health report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -29% stronger than usual.
Does Fractyl Health pay a dividend?
No, Fractyl Health currently does not pay a dividend.
Which stocks are comparable to Fractyl Health?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Fractyl Health stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fractyl Health against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.